NASDAQ:ARDXArdelyx Stock Price, Forecast & News

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 6.7% and is now trading at $5.58.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ardelyx.

Ardelyx is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Ardelyx.

Ardelyx Inc (NASDAQ:ARDX) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.01. Ardelyx had a negative return on equity of 65.94% and a negative net margin of 1,090.69%.
View Ardelyx's earnings history.

5 brokers have issued 12 month price targets for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 115.1% from the stock's current price.
View analysts' price targets for Ardelyx.

Media coverage about ARDX stock has been trending extremely negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ardelyx earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Ardelyx.

Ardelyx saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,210,000 shares, an increase of 14.2% from the February 13th total of 2,810,000 shares. Based on an average daily volume of 870,300 shares, the days-to-cover ratio is currently 3.7 days.
View Ardelyx's Short Interest.

Some companies that are related to Ardelyx include Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Revance Therapeutics (RVNC), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Corcept Therapeutics (CORT) and INDIVIOR PLC/S (INVVY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX) and Catalyst Pharmaceuticals (CPRX).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include NEA Management Company LLC (15.33%), Goldman Sachs Group Inc. (0.74%), Bailard Inc. (0.52%), Bank of New York Mellon Corp (0.33%), Teacher Retirement System of Texas (0.20%) and California Public Employees Retirement System (0.19%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab and Scott D Sandell.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, EAM Investors LLC, Goldman Sachs Group Inc., Bailard Inc., Strs Ohio, UBS Group AG, and SG Americas Securities LLC. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Mark Kaufmann, Michael Raab, and Scott D Sandell.
View insider buying and selling activity for Ardelyx.

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Teacher Retirement System of Texas, Swiss National Bank, Alps Advisors Inc., Hamilton Lane Advisors LLC, Principal Financial Group Inc., California Public Employees Retirement System, Bank of New York Mellon Corp, and Rafferty Asset Management LLC.
View insider buying and selling activity for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $5.58.

Ardelyx has a market capitalization of $497.41 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]